Preclinical evaluation of oncolytic potential human rotavirus Wt 1-5 in gastric adenocarcinoma.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 17 11 2022
accepted: 25 04 2023
medline: 17 5 2023
pubmed: 15 5 2023
entrez: 15 5 2023
Statut: epublish

Résumé

Despite advances in biomedical research, gastric cancer remains the leading cause of morbidity and mortality worldwide due to the limited efficacy of conventional therapies. In recent decades, oncolytic viruses have emerged as a biological therapeutic alternative to cancer due to their selectivity, effectiveness, and low toxicity. However, clinical trials have shown that developing a virus with selectivity for multiple tumor receptors and the ability to penetrate and diffuse through the tumor microenvironment to reactivate the immune system remains challenging. This study aimed to examine the oncolytic potential of tumor cell-adapted rotavirus Wt1-5 in gastric adenocarcinoma samples. This study focused on determining the propagation capacity of the RV Wt1-5 through the tumor and the importance of the expression of cell surface co-receptors, including integrin β3, protein disulfide isomerase (PDI), and heat shock proteins (Hsp-90, -70, -60, -40, and Hsc 70), during infection of tumor cells. These proteins were found to be differentially expressed in tumor cells compared to adjacent non-tumor cells. Preincubation of gastric tumor cells with antibodies against these proteins decreased rotavirus infections, validating their importance in the binding and entry of RV Wt1-5 into tumor cells, as previously reported. Upon RV infection, apoptosis was one of the types of death that was observed. This was evidenced by evaluating the expression of CASP-3, -9, PARP, cytochrome C, Bax, Bid, p53, and Bcl-2, as well as observing morphological changes such as chromatin margination, nuclear condensation, and fragmentation. Finally, at 60 h.p.i, histological analysis revealed that oncolysis compromised the entire thickness of the tumor. Therefore, the results suggest that RV Wt1-5 could be a novel therapeutic agent co-adjuvant agent for conventional and targeted therapies in managing GC. Ex vivo infection of the tumor tissue model showed characteristics of an immune response that could be explored in future studies.

Identifiants

pubmed: 37186587
doi: 10.1371/journal.pone.0285543
pii: PONE-D-22-31744
pmc: PMC10184912
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0285543

Informations de copyright

Copyright: © 2023 Sossa-Rojas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Clin Lab Med. 2015 Jun;35(2):363-91
pubmed: 26004648
Nat Rev Drug Discov. 2016 Aug 30;15(9):660
pubmed: 30907381
Oncolytic Virother. 2020 Mar 06;9:1-15
pubmed: 32185149
Ann Surg. 2005 Jan;241(1):27-39
pubmed: 15621988
Tumour Biol. 2016 Mar;37(3):3155-61
pubmed: 26427658
Cancer Med. 2023 Jan;12(2):1520-1531
pubmed: 35864742
Oxid Med Cell Longev. 2022 Sep 24;2022:8611306
pubmed: 36193075
Acta Virol. 2020;64(1):44-58
pubmed: 32180418
J Virol. 1986 May;58(2):700-3
pubmed: 2422398
J Cancer. 2021 Mar 1;12(8):2456-2464
pubmed: 33758622
Front Immunol. 2017 May 15;8:555
pubmed: 28555136
Acta Virol. 2012;56(1):63-70
pubmed: 22404611
Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):e12-e13
pubmed: 27093452
Curr Protoc Microbiol. 2009 Nov;Chapter 15:Unit 15C.3
pubmed: 19885940
Cancer Immunol Res. 2014 Apr;2(4):295-300
pubmed: 24764576
Surgery. 2007 Jan;141(1):41-50
pubmed: 17188166
J Vis Exp. 2018 Oct 12;(140):
pubmed: 30371673
Curr Opin Virol. 2021 Jun;48:42-48
pubmed: 33887683
Onco Targets Ther. 2018 Jan 15;11:351-359
pubmed: 29391812
Virology. 2000 Dec 5;278(1):50-4
pubmed: 11112480
Colomb Med (Cali). 2021 Mar 16;52(1):e2024196
pubmed: 33911319
Front Cell Dev Biol. 2022 Feb 09;9:816230
pubmed: 35223869
Oncol Lett. 2015 Mar;9(3):1154-1158
pubmed: 25663872
Nat Rev Dis Primers. 2017 Nov 09;3:17083
pubmed: 29119972
Intervirology. 2012;55(6):451-64
pubmed: 22398681
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14644-9
pubmed: 11114176
Front Immunol. 2022 Apr 07;13:814491
pubmed: 35464475
Arch Virol. 2013 Jun;158(6):1323-36
pubmed: 23404461
Biomedicines. 2020 Jul 24;8(8):
pubmed: 32722005
Biomedica. 2020 Jun 15;40(2):362-381
pubmed: 32673463
Onco Targets Ther. 2020 Feb 03;13:1011-1025
pubmed: 32099404
Arch Virol. 2011 Aug;156(8):1397-413
pubmed: 21597953
Cancer Lett. 2020 Jan 28;469:134-141
pubmed: 31669516
Curr Opin Biotechnol. 2020 Oct;65:25-36
pubmed: 31874424
Front Oncol. 2014 Apr 10;4:74
pubmed: 24782985
Oncolytic Virother. 2018 Sep 05;7:79-93
pubmed: 30234074
Oncogene. 2003 Dec 8;22(56):9030-40
pubmed: 14663481
Oncotarget. 2017 Apr 4;8(14):23996-24008
pubmed: 28177918
PLoS One. 2017 Jul 24;12(7):e0181871
pubmed: 28738064
J Immunol Res. 2014;2014:953203
pubmed: 24741635
Am J Cancer Res. 2017 May 01;7(5):1016-1036
pubmed: 28560055
BMC Gastroenterol. 2021 Nov 22;21(1):437
pubmed: 34809574
J Virol. 2013 Jun;87(12):6840-50
pubmed: 23576507
Mol Ther. 2011 May;19(5):886-94
pubmed: 21364541
PLoS One. 2016 Feb 01;11(2):e0147666
pubmed: 26828934
Front Oncol. 2021 Dec 22;11:761015
pubmed: 35004284
J Gen Virol. 2013 Jun;94(Pt 6):1151-1160
pubmed: 23486667
Cell Calcium. 2009 Jul;46(1):1-17
pubmed: 19535138
World J Gastroenterol. 2014 Feb 21;20(7):1635-49
pubmed: 24587643
Front Oncol. 2020 Sep 09;10:1786
pubmed: 33014876
Acta Biochim Biophys Sin (Shanghai). 2021 Aug 31;53(9):1216-1226
pubmed: 34363072
Mol Ther. 2007 Sep;15(9):1686-93
pubmed: 17579581
CA Cancer J Clin. 2020 Jul;70(4):313
pubmed: 32767693
ESMO Open. 2020 Aug;5(4):
pubmed: 32817133
Arch Virol. 2007;152(12):2183-96
pubmed: 17876681
Biochemistry. 1987 Feb 10;26(3):731-6
pubmed: 3567146
Cancer Lett. 2003 Aug 20;198(2):219-28
pubmed: 12957361
Cancers (Basel). 2021 Jun 02;13(11):
pubmed: 34199429
Acta Virol. 2020;64(4):433-450
pubmed: 33112641
Virology. 1998 Dec 5;252(1):17-27
pubmed: 9875312
BMC Gastroenterol. 2009 Feb 09;9:14
pubmed: 19203381
J Hematol Oncol. 2020 Jun 29;13(1):84
pubmed: 32600470
J Virol. 2002 Apr;76(8):4096-102
pubmed: 11907249
J Virol. 2003 Jul;77(13):7254-60
pubmed: 12805424
Cell Death Differ. 2018 Jan;25(1):104-113
pubmed: 29149101
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
J Virol. 2002 Feb;76(3):1109-23
pubmed: 11773387
J Oncol. 2019 Jun 9;2019:6270784
pubmed: 31281359
Biomedica. 2011 Mar;31(1):70-81
pubmed: 22159485
Folia Microbiol (Praha). 2021 Aug;66(4):623-638
pubmed: 33950511
Virology. 2015 May;479-480:75-84
pubmed: 25724417
Virol J. 2010 Nov 29;7:350
pubmed: 21114853
Nat Rev Cancer. 2002 Aug;2(8):594-604
pubmed: 12154352
Onco Targets Ther. 2020 May 12;13:4075-4088
pubmed: 32494161
J Vis Exp. 2011 Jun 25;(52):
pubmed: 21730946
Niger J Clin Pract. 2019 Dec;22(12):1698-1705
pubmed: 31793477

Auteurs

Henry Sossa-Rojas (H)

Departamento de Ciencias Básicas y Medicina Oral, Facultad de Odontología, Universidad Nacional de Colombia, Sede Bogotá, Bogotá, D.C., Colombia.

Pedro Gabriel Franco-Maz (PG)

Departamento de Morfología, Facultad de Medicina, Universidad Nacional de Colombia, Sede Bogotá, Bogotá, D.C., Colombia.
Servicio de Patología, Hospital Universitario La Samaritana, Bogotá, D.C., Colombia.

Carlos Zapata-Acevedo (C)

Departamento de Cirugía, Facultad de Medicina, Universidad Nacional de Colombia, Sede Bogotá, Bogotá, D.C., Colombia.
Servicio de Cirugía General, Hospital Universitario La Samaritana, Bogoté, D.C., Colombia.

Luz Dary Gutierrez-Castañeda (LD)

Research Institute, Grupos Ciencias Básicas en Salud - CBS-FUCS, Fundación Universitaria de Ciencias de la Salud, Hospital Infantil Universitario de San Josá, Bogotá, D.C., Colombia.

Carlos Guerrero (C)

Departamento de Ciencias Fisiológicas, Facultad de Medicina, Universidad Nacional de Colombia, Sede Bogotá, Bogotá, D.C., Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH